Home | Welcome to Contract Pharma   
Last Updated Friday, July 11 2014
Print

Search Results for 'Financial Report: Sanofi'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published April 29, 2014
Exchange rates hurt results Read More »
By Gil Roth
Published February 6, 2014
Diabetes, Genzyme, Generics key drivers Read More »
Published October 30, 2013
Product sales up for the first time in five quarters Read More »
Published August 1, 2013
Generic competition, Brazil issue impact results Read More »
Published May 2, 2013
Generic competition continues to hurt revenues Read More »
Published February 7, 2013
Revenues up 3% in the quarter, earnings hurt by generics Read More »
Published October 25, 2012
Genzyme revenues staunch patent losses Read More »
Published February 8, 2012
Genzyme revenues, growth offset generic impact on flagship products Read More »
Published February 10, 2010
Pharmaceutical sales were $9.0 billion (+3%) in 4Q09 and $37.0 billion (+4%) for FY09. Read More »
Published November 1, 2006
Sanofi-Aventis 3Q 3Q Revenues: $8.8 billion (-1%) 3Q Earnings: $1.5 billion YTD Revenues: $26.7 billion (+3%) YTD Earnings: $4.4 billion (+100%) Comments: 3Q net sales for the pharmaceuticals business were hit hard by the introduction… Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On